anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide an external preparation for skin, excellent in a moisture retainability-imparting force in an extent for improving wrinkles.  <P>SOLUTION: This external preparation for the skin is characterized by containing (1) amodimethicone and (2) a polyglycerol. The polyglycerol is preferably diglycerol. The external preparation for the skin is preferably in an emulsifier form. It is further preferable that the external preparation for the skin contains an alkyl-modified carboxyvinyl polymer and/or its salt. It is further preferable that the external preparation for the skin contains ubidecarenone and/or α-lipoic acid. The ubidecarenone is preferably contained in the form of vesicle. It is further preferable that the vesicle contains a hydrogenated phospholipid and phytosterol in addition to the ubidecarenone.  <P>COPYRIGHT: (C)2008,JPO&INPIT
It is recommended that the prescribing physician relate the following information to patients being treated with naltrexone:

You have been prescribed naltrexone hydrochloride tablets as part of the comprehensive treatment for your alcoholism or drug dependence. You should carry identification to alert medical personnel to the fact that you are taking naltrexone hydrochloride. A naltrexone medication card may be obtained from your physician and can be used for this purpose. Carrying the identification card should help to ensure that you can obtain adequate treatment in an emergency. If you require medical treatment, be sure to tell the treating physician that you are receiving naltrexone therapy.

You should take naltrexone as directed by your physician. If you attempt to self-administer heroin or any other opiate drug, in small doses while on naltrexone, you will not perceive any effect. Most important, however, if you attempt to self-administer large doses of heroin or any other opioid (including methadone or LAAM) while on naltrexone, you may die or sustain serious injury, including coma.

Naltrexone is well-tolerated in the recommended doses, but may cause liver injury when taken in excess or in people who develop liver disease from other causes. If you develop abdominal pain lasting more than a few days, white bowel movements, dark urine, or yellowing of your eyes, you should stop taking naltrexone immediately and see your doctor as soon as possible.
A vaccine compsn. contains an immunogenic agent and an adjuvant comprising a monomer (or oligomeric deriv.) contg. the N-acyl-muramic acid gp. in which the acyl gp. is glycolyl or acetyl, and a peptide chain comprising 2-8 amino acids. The first of the amino acids, bonded to the N-acyl muramic acid, comprises alanine, serine or glycine and the second comprises glutamic acid or aspartic acid. The adjuvants are esp. effective for stimulating immune response, to immunise man and warm blodded animals against bacterial, viral and parasitic infections and against tissue antigens of normal or pathologic orign esp. tumours.
<P>PROBLEM TO BE SOLVED: To provide a technology for inhibiting the generation of mRNA of an SREB-1, and thereby preventing the formation of fatty liver.  <P>SOLUTION: This sterol regulatory element-binding protein-1 (SREB-1) expression inhibitor is provided by consisting of royal jelly. The SREB-1 expression inhibitor is incorporated into a food. Such the food has an effect of preventing the fatty liver formation. The product form of such the food preferably has a display telling that the food has the effect of inhibiting the expression of the SREB-1 and thereby inhibiting the construction of cholesterol into liver cells and preventing the fatty liver.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Doxycycline hyclate, USP is an antibacterial drug synthetically derived from oxytetracycline for oral administration. 

The structural formula of doxycycline monohydrate is

with a molecular formula of C 22H 24N 2O 8•H 2O and a molecular weight of 462.46. The chemical designation for doxycycline is 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrate. The molecular formula for doxycycline hydrochloride hemiethanolate hemihydrate is (C 22H 24N 2O 8•HCl) 2•C 2H 6O•H 2O and the molecular weight is 1025.89. 

Doxycycline, USP is a light-yellow crystalline powder. Doxycycline hyclate, USP is soluble in water.

Doxycycline, USP has a high degree of lipoid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline, USP will not degrade into an epianhydro form. 

Inert ingredients in the capsule formulations are: magnesium stearate, microcrystalline cellulose and sodium lauryl sulfate. The hard gelatin capsule shells contains: FD&C Blue 1, gelatin, sodium lauryl sulfate and titanium dioxide. The printing ink contains: black iron oxide, potassium hydroxide, propylene glycol, shellac and strong ammonia solution.
### PREGNANCY CATEGORY C

No effects on teratogenicity or embryotoxicity were observed in female rats given oral doses up to 7 mg/kg/day, which is approximately 3-fold higher than the human dose of 2-4 mg every 4 to 6 hours for the tablet on a body surface area basis. Hydromorphone produced skull malformations (exencephaly and cranioschisis) in Syrian hamsters given oral doses up to 20 mg/kg during the peak of organogenesis (gestation days 8-9). The skull malformations were observed at doses approximately 7-fold higher than the human dose of 2-4 mg every 4 to 6 hours for the tablet on a body surface area basis. There are no adequate and well-controlled studies of hydromorphone hydrochloride tablets in pregnant women.

Hydromorphone crosses the placenta, resulting in fetal exposure. Hydromorphone hydrochloride tablets should be used in pregnant women only if the potential benefit justifies the potential risk to the fetus (see Labor and Delivery and DRUG ABUSE AND DEPENDENCE).
T2DM patients will receive Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
Pregnancy Category C. Oral doses of besifloxacin up to 1000 mg/kg/day were not associated with visceral or skeletal malformations in rat pups in a study of embryo-fetal development, although this dose was associated with maternal toxicity (reduced body weight gain and food consumption) and maternal mortality. Increased post-implantation loss, decreased fetal body weights, and decreased fetal ossification were also observed. At this dose, the mean Cmax in the rat dams was approximately 20 mcg/mL, >45,000 times the mean plasma concentrations measured in humans. The No Observed Adverse Effect Level (NOAEL) for this embryo-fetal development study was 100 mg/kg/day (Cmax, 5 mcg/mL, >11,000 times the mean plasma concentrations measured in humans).

In a prenatal and postnatal development study in rats, the NOAELs for both fetal and maternal toxicity were also 100 mg/kg/day. At 1000 mg/kg/day, the pups weighed significantly less than controls and had a reduced neonatal survival rate. Attainment of developmental landmarks and sexual maturation were delayed, although surviving pups from this dose group that were reared to maturity did not demonstrate deficits in behavior, including activity, learning and memory, and their reproductive capacity appeared normal.

Since there are no adequate and well-controlled studies in pregnant women, Besivance™ should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
AVANDAMET: AVANDAMET combines 2 antidiabetic agents with different mechanisms of action to improve glycemic control in patients with type 2 diabetes: Rosiglitazone, a member of the thiazolidinedione class, and metformin, a member of the biguanide class. Thiazolidinediones are insulin sensitizing agents that act primarily by enhancing peripheral glucose utilization, whereas biguanides act primarily by decreasing endogenous hepatic glucose production.

Rosiglitazone: Rosiglitazone improves glycemic control by improving insulin sensitivity. Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator–activated receptor-gamma (PPARγ). In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPARγ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In addition, PPARγ-responsive genes also participate in the regulation of fatty acid metabolism.

Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes. The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues. Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat. 

In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin's action in the liver, muscle, and adipose tissue. Pharmacologic studies in animal models indicate that rosiglitazone improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue. Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.

Metformin: Metformin is an antidiabetic agent, which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Its pharmacologic mechanisms of action are different from other classes of oral antidiabetic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and increases peripheral glucose uptake and utilization. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects except in special circumstances [see Warnings and Precautions (5.11)] and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease.
The reported incidence of allergic reactions to all penicillins ranges from 0.7 to 10 percent in different studies (see WARNINGS). Sensitization is usually the result of previous treatment with a penicillin, but some individuals have had immediate reactions when first treated. In such cases, it is postulated that prior exposure to penicillin may have occurred via trace amounts present in milk or vaccines.

Two types of allergic reactions to penicillin are noted clinically – Immediate and delayed.

Immediate reactions usually occur within 20 minutes of administration and range in severity from urticaria and pruritus to angloneurotic edema, laryngospasm, bronchospasm, hypotension, vascular collapse and death (see WARNINGS). Such immediate anaphylactic reactions are very rare and usually occur after parenteral therapy, but a few cases of anaphylaxis have been reported following oral therapy. Another type of immediate reaction, an accelerated reaction, may occur between 20 minutes and 48 hours after administration and may include urticaria, pruritus, fever and, occasionally, laryngeal edema.

Delayed reactions to penicillin therapy usually occur within 1 to 2 weeks after initiation of therapy. Manifestations include serum sickness-like symptoms, i.e., fever, malaise, urticaria, myalgia, arthralgia, abdominal pain and various skin rashes, ranging from maculopapular eruptions to exfoliative dermatitis.

Contact dermatitis has been observed in individuals who prepare penicillin solutions.
Cytomegalovirus (CMV) is a type of double-stranded deoxyribonucleic acid virus belonging to the herpesviridae family. Following a primary infection, the virus becomes latent in various types of white blood cells. Cytomegalovirus infection can remain latent or become active, especially in immunocompromised individuals, such as those undergoing hematopoietic stem cell transplantation (HSCT), where CMV reactivation can occur. In this context, CMV infection is common and associated with high rates of morbidity and mortality. Pneumonia is one of the most serious complications, with mortality rates exceeding 50%. Additionally, even in the absence of organ-specific disease, CMV infection is related to increased mortality unrelated to hematologic neoplasm recurrence. Given the frequency and severity of this infection in HSCT patients, it is crucial to implement effective strategies for monitoring, prevention, and treatment. This guideline was developed to identify patient groups that benefit from a systematic approach to CMV infection and to define the most appropriate strategy for each group. Monitoring CMV viral load in peripheral blood is crucial, especially in patients at moderate to high risk of active infection. Primary prophylaxis with letermovir (an antiviral drug) is recommended to reduce the incidence of active infection, especially in high-risk patients. Secondary prophylaxis with valganciclovir (antiviral drug) is recommended after an episode of active infection, while preemptive and disease treatment is based on monitoring viral load and clinical response. The aim of this guideline is to improve the approach to CMV infection in HSCT patients, ensuring an effective and safe preventive and therapeutic approach.
In PrPD, the stomach is divided just above the pylorus ring. the nearly total stomach more than 95% was preserved.
The invention discloses a method, equipment and a storage medium for evaluating an illness, and relates to the field of medical treatment. The method comprises the steps of sending a state test instruction to a first client after obtaining authorization information, wherein the state test instruction comprises a test video segment and a test text, and the test video segment and the test text sent by the same first client are dynamically changed. User status information determined in response to the status test instruction is then received and stored. And then inquiring a plurality of pieces of user state information stored in the first client within a preset time period, matching the state evaluation rule and determining the state evaluation value of the user within the preset time period. And finally, judging whether the state of the user meets the disease-free condition according to the state evaluation value, determining a judgment result and determining whether to send disease-free early warning information to the second client side in real time. Therefore, if the user receives the early warning information of the disease, the early warning information can be timely adjusted or intervention treatment can be carried out in advance, and the early warning information plays a role in preventing the disease from occurring in advance.
ABSTRACT OF THE DISCLOSURE A living, attenuated, oral vaccine system is described for the immunization against enteric disease.  This oral vaccine is a genetic hybrid derivative of an attenuated galactose epimeraseless strain of S. typhi which carries at least one protective antigen other than normal somatic S. typhi antigens.          The oral vaccine can provide protection against both typhoid fever and at least one other enteric disease.  A bivalent oral vaccine is described wherein the non-typhoid protective antigen is the plasmid-encoded form I antigen of Shigella sonnei.  A protective antigen from Shigella sonnei was transferred to a streptomycin resistant mutant of S. typhi strain Ty21a.  The transconjugant S. typhi strain expressed both S. typhi and S. sonnei antigens and protected experimental animals against lethal infections with either S. typhi or S. sonnei.  This strain is considered to be useful as a vaccine against typhoid fever and bacillary dysentery caused by S. sonnei.
7.1 Pregnancy

Trubrexa TMTransdermal Patch has not been studied in pregnancy. Maternal use is not expected to result in fetal exposure. Animal studies have shown no adverse effects when lidocaine and capsaicin are administered and absorbed. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Trubrexa TMTransdermal Patch should only be used during pregnancy if clearly needed or advised by a healthcare professional. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. 

7.2 Lactation

Trubrexa TMTransdermal Patch has not been studied in nursing mothers. Lidocaine is excreted in human milk, and the milk:plasma ration of lidocaine is 0.4. Capsaicin is negligibly absorbed systemically by the mother following topical administration of Trubrexa TMTransdermal Patch. Caution should be exercised when Trubrexa TMTransdermal Patch is administered to a nursing woman. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Trubrexa TMTransdermal Patch and any potential adverse effects on the breastfed infant. 

7.3 Pediatric Use

Safety and effectiveness in pediatric patients under the age of 12 have not been studied or established.

7.4 Geriatric Use

Safety and effectiveness are similar in geriatric patients and younger patients. No dose adjustments are required in geriatric patients.
A tumor suppressive composition active against lymphoma consisting of an injection of hybrid protein anti Thy 1.2 monoclonal antibody-ricin and hyperosmotic lactose. The inoculation i.v. of murine tissues in vivo by lymphoma is made at -20 to -25 days and the tumor suppressant composition is used i.v. at Day 1 in an amount of 1-3 μg of anti Thy monoclonal antibody-ricin together with sufficient hyperosmotic lactose to raise the lactose level to 20-30 mM. The broad purpose of this invention is to modify the receptor specificity of a potent toxin such as ricin by coupling it with a monoclonal antibody directed at a specific tumor or differentiation antigen. The object here is to use the reagent to selectively kill tumor cells without affecting normal cells.
Patients receive azacitidine via nebulizer over 20 minutes QD on days 1-5 and 15-19. Treatment repeats every 28 days for up to 24 weeks in the absence of disease progression or unacceptable toxicity. Patients may continue treatment on a case-by-case basis at the discretion of principal investigator and Institutional Review Board.
PURPOSE: A healthcare system using the home network and an operating method thereof are provided to collect health information received from a hospital server by a home gateway server and to control a home device according to the health information, thereby providing temperature, humidity, and a menu beneficial to the health condition of user. CONSTITUTION: When the health information update cycle of user is reached, a home gateway server requests health information for at least one registered user to a hospital server and receives the health information from the hospital server (601-605). If the received user health information and user health information received in a previous update cycle are not matched, the home gateway server analyzes the user health information to generate environmental control information and health help information (607,609). The home gateway server transmits the environmental control information to corresponding home devices and transmits the health help information to a plurality of mobile terminals (611). [Reference numerals] (601) Is it a time for renewing health information ?; (603) Request for health information; (605) Receive health information; (607) Is health information renewed?; (609) Generate control information by analyzing health information; (611) Transmit the control information to home appliances; (AA) Start; (BB,DD) No; (CC,EE) Yes
Intra-abdominal pressure will be set to 7-10 mmHg during the surgery. Deep neuromuscular block will be induced by rocuronium bolus 1 mg/kg, maintained by a continuous infusion of rocuronium (0.6mg/kg/h), and titrated towards PTC 1-2.
Participants were administered with AIN457 (Sp2/0 or Chinese hamster ovary cell (CHO) derived) 10 mg/kg, (CHO derived) 3 mg/kg or (CHO derived) 1 mg/kg i.v. dose on Day 1 and if needed a second dose of AIN457 10 mg/kg i.v. dose either on Day 15 or Day 22. 3 participants from cohort 1 rolled on into this cohort.
PURPOSE:To provide a hair dressing or skin cosmetic having improved water- solubility, stability and yield, etc., of extract of SEMBURI (Swertia japonica), and containing a water-soluble extract of SEMBURI produced by hydrolyzing the whole grass of SEMBURI and optionally fermenting the hydrolyzed product with yeast. CONSTITUTION:The objective hair dressing or skin cosmetic contains (A) a water-soluble extract produced by hydrolyzing the whole grass of SEMBURI or (B) a water-soluble extract produced by hydrolyzing the whole grass of SEMBURI and fermenting the hydrolyzed product with yeast. The extract promotes the peripheral blood flow at a small amount, tightens the skin, gives rosy and blooming skin and promotes the development (growth) of hair when rubbed into the scalp. It controls the secretion from skin and prevents acne or suffusion (swelling) of secretory gland or hair root which is a premonitory symptom of acne. It can be extracted in improved yield compared with conventional method and has excellent water-solubility and stability. Especially, the product using the substance B is suitable for compounding into various preparations because of its excellent fragrance.
In a medical network management system (NMS) (20), health plan beneficia-ries access a team of health care profes-sionals over the telephone to help them assess their health needs and select ap-propriate care. The NMS (20) has a pa-tient assessment component (22). The pa-tient assessment component consists of a set of information tools which are used by health care professionals to assess pa-tient conditions and assist in the selection of health care services and to help pa-tients find appropriate care at the appropri-ate time. The tools include a comprehen-sive, automated set of proprietary assess-ment algorithms (26) which are based on branched chain algorithms utilizing Bayes theorem. These unique, clinical tools en-able a trained nurse or other health care professional to sort patients into differ-ent risk categories, safely and effectively without requiring a medical diagnosis. Pa-tients can then be guided to an appropriate level and type of care for their problem(s) based on their level of risk and set of po-tential needs.
The utility model discloses plant chewing gum which is provided with a licorice sheet, a honey layer and a milk vetch sheet, wherein the honey layer is clipped between the licorice sheet and the milk vetch sheet, and used for pasting the licorice sheet together with the milk vetch sheet. Licorice can remove large heat, purge the sthenic heart-fire, eliminate the pharyngalgia and nourish insufficiency of the spleen and stomach; milk vetch is favorable for the stomach gas; honey can clear heat, remove toxin and cure infants' decayed teeth, and lip and mouth ulcers. Because the components are beneficial for mouth cavity and stomach health, long term use can eradicate the halitosis. The components are also advantageous for health of other body organs, so long term use can build and strengthen the body. The plant chewing gum can be conveniently fabricated: cut licorice sheets and milk vetch can be directly purchased in a drugstore, and the honey is clipped in between. The plant chewing gum can also be conveniently eaten.